Literature DB >> 4031294

Lack of objective improvement in ventricular systolic function in patients with myocarditis treated with azathioprine and prednisone.

J D Hosenpud, J H McAnulty, N R Niles.   

Abstract

Six patients with myocarditis documented by biopsy, after a baseline right heart catheterization and echocardiogram, underwent treatment with azathioprine and prednisone. After 3 months of treatment, biopsy, right heart catheterization and echocardiogram were repeated. In addition to the immunosuppressive therapy, most patients received additional conventional medications for heart failure between evaluation periods (mean number of cardiac drugs increased from 1.7 +/- 1.0 to 2.7 +/- 0.05, p = 0.041). Mean heart rate decreased (105 +/- 14 to 84 +/- 13 beats/min, p = 0.016), as did pulmonary wedge pressure (23 +/- 8 to 12 +/- 4 mm Hg, p = 0.012). There were no significant changes in cardiac index (3.1 +/- 0.8 to 2.9 +/- 1.0 liters/min), end-diastolic dimension (62 +/- 13 to 62 +/- 12 mm) or fractional shortening (11 +/- 6 to 12 +/- 3%) with treatment. Complications from immunosuppressive therapy included severe soft tissue infection, acute psychosis and adrenal insufficiency in one patient each. The benefits from prednisone and azathioprine in this group of patients have not been demonstrated. Although heart rate and pulmonary wedge pressure decreased, these changes could be ascribed to increases in the conventional therapy for heart failure. Finally, there is a high incidence of side effects from prednisone and azathioprine therapy. These findings suggest that this unproven therapy for myocarditis should be limited to experimental protocols.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031294     DOI: 10.1016/s0735-1097(85)80485-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

1.  Myocarditis: some current perspectives and future directions.

Authors:  H A McAllister
Journal:  Tex Heart Inst J       Date:  1987-12

Review 2.  Therapeutic implications of immune mechanisms in myocarditis.

Authors:  J B O'Connell; J W Mason
Journal:  Springer Semin Immunopathol       Date:  1989

Review 3.  [Therapy of dilated cardiomyopathies with and without inflammation].

Authors:  G Hufnagel; S Pankuweit; B Maisch
Journal:  Med Klin (Munich)       Date:  1998-04-15

4.  Relation between histological findings on early repeat right ventricular biopsy and ventricular function in patients with myocarditis.

Authors:  G W Dec; J T Fallon; J F Southern; I F Palacios
Journal:  Br Heart J       Date:  1988-10

Review 5.  Recognition and optimum management of myocarditis.

Authors:  A L Caforio; W J McKenna
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

6.  Varicella zoster myocarditis progressing to cardiomyopathy and cardiac transplantation.

Authors:  A Tsintsof; W J Delprado; A M Keogh
Journal:  Br Heart J       Date:  1993-07

Review 7.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 8.  Diagnosing and treating active myocarditis.

Authors:  J B O'Connell; J W Mason
Journal:  West J Med       Date:  1989-04

9.  Verapamil ameliorates the clinical and pathological course of murine myocarditis.

Authors:  R Dong; P Liu; L Wee; J Butany; M J Sole
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 10.  [State of diagnostics and therapy of inflammatory cardiomyopathie].

Authors:  H P Schultheiss; U Kühl
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.